Cinaciguat

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Cinaciguat (BAY 58-2667) 是临床开发中第一种新型可溶性鸟苷酸环化酶 (sGC) 激活剂，用于治疗急性失代偿性心力衰竭。

Cinaciguat (BAY 58-2667) is the first of a new class of soluble guanylate cyclase (sGC) activators in clinical development for acute decompensated heart failure.(In Vitro):Cinaciguat (10 μM) significantly enhances intracellular cGMP generation. Cinaciguat does not dose-dependent effects on cell contraction and calcium transients.(In Vivo):Cinaciguat (10 mg/kg/day, p.o.) treatment in diabetic rats does not influence blood glucose levels, but leads to attenuated water intake. Cinaciguat treatment alleviates diabetes mellitus related oxidative stress, protects against DM related alteration of the NO-sGC-cGMP-PKG signalling, and alleviates DM related myocardium hypertrophy and apoptosis. Cinaciguat (1-10-100 nM) induces concentration-dependent relaxations in strips from both WT and apo-sGC mice, but does not have any effect on phasic activity induced by PGF2α in WT or apo-sGC strips.

——

——

——

Others

Other Targets

sGC

Cardiovascular Disease

——

329773-35-5

565.7

C36H39NO5

>98% (HPLC)

DMSO: 10 mM

OC(=O)CCCCN(CCC1=CC=CC=C1OCC1=CC=C(CCC2=CC=CC=C2)C=C1)CC1=CC=C(C=C1)C(O)=O

——

(-20℃)

With Ice Pack

≥ 2 years